All In Biotech

Drug Trial Radar · NCT02927067

A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants

A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients

Last checked: Nov 19, 2026Latest source record: Mar 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 553 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

553

Actual

Start

Apr 14, 2017

Primary completion

Jul 1, 2022

Study completion Jul 1, 2022

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
Collaborators
Takeda Development Center Americas, Inc.
First posted
Oct 6, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is about treatment options for cytomegalovirus infections in people who have received stem cell transplants. The main aim of the study is to check if the cytomegalovirus infection can no longer be detected after treatment with marivabir or valganciclovir. Participants will take 2 tablets of marivabir or valganciclovir and 2 tablets of placebo twice a day for 8 weeks. A placebo will look like marivabir or valganciclovir but will not have any medicine in it. After treatment, each participant will be followed up for up to 12 weeks. Participants will visit their study clinic up to 18 times during the study.

Conditions

  • Cytomegalovirus (CMV)

Interventions

  • MaribavirDrug

    Participants will receive 400 mg of maribavir BID orally.

  • ValganciclovirDrug

    Participants will receive valganciclovir tablets orally.

  • PlaceboOther

    Participants will receive placebo tablets matched to either maribavir or valganciclovir.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Achieved Confirmed Clearance of Plasma Cytomegalovirus (CMV) Deoxyribose Nucleic Acid (DNA) at the End of Study Week 8Time frame: Week 8

Locations

129 sites in 23 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • UCLA Medical Center

    Los Angeles, California

  • Stanford University

    Stanford, California

  • Colorado Blood Cancer Institute - PPDS

    Denver, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • Emory University

    Atlanta, Georgia

  • University of Chicago

    Chicago, Illinois

  • Loyola University Medical Center

    Maywood, Illinois

  • University of Maryland School of Medicine

    Baltimore, Maryland

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Brigham and Womens Hospital

    Boston, Massachusetts

  • UMass Memorial Medical Center

    Worcester, Massachusetts

  • Harper University Hospital

    Detroit, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic - PIN

    Rochester, Minnesota

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Joan and sandford I. Weill Medical College of Cornell University Clinic

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • TriStar Centennial Medical Center

    Nashville, Tennessee

  • Saint Davids South Austin Medical Center

    Austin, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Texas Transplant Institute

    San Antonio, Texas

  • VA Puget Sound Health Care System - NAVREF - PPDS

    Seattle, Washington

  • The Medical College of Wisconsin, Inc.

    Milwaukee, Wisconsin

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Elisabethinen Hospital Linz

    Linz, Austria

  • Medizinische Universitat Wien (Medical University of Vienna)

    Vienna, State of Vienna, Austria

  • CHU de Liège

    Liège, Belgium

  • UZ Antwerpen

    Edegem, Antwerpen, Belgium

  • Institute Jules Bordet

    Brussels, Brussels Capital, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, Brussels Capital, Belgium

  • Universitair Ziekenhuis Brussel - PIN

    Jette, Brussels Capital, Belgium

  • University Hospital Gent

    Ghent, Oost-Vlaanderen, Belgium

  • UZ Leuven

    Leuven, Vlaams Brabant, Belgium

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.